ArticleEye (London, England)2022
The Royal College of Ophthalmologists Commissioning guidelines on age macular degeneration: executive summary.
Article in Eye (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Rerouting Eye Care: How AI and Telemedicine Are Reshaping Ophthalmology Patient Journeys in the United Kingdom and Germany.Journal of medical Internet research · 2026Article
- Leveraging structured EMR data for efficient patient prescreening: a practical approach to reducing screen-failure rates in Light Touch Trial.Eye (London, England) · 2026Article
- Pharmacoproteomics in the development of personalised medicine in Age-related Macular Degeneration (PHARPRO-AMD) study protocol.BMJ open ophthalmology · 2025Article
- ChatGPT-4 for addressing patient-centred frequently asked questions in age-related macular degeneration clinical practice.Eye (London, England) · 2025Article
- Validation of the Chinese version of the financial toxicity scale in patients with wet age-related macular degeneration.Journal of patient-reported outcomes · 2025Article
- The quality, accuracy and appropriateness of UK optometric age-related macular degeneration referrals.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Article
- Verteporfin Photodynamic Therapy for the Treatment of Chorioretinal Conditions: A Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- A Novel Optometry-Led Decision-Making Community Referral Refinement Scheme for Neovascular Age-Related Macular Degeneration Screening.Clinical optometry · 2024Article
- The NOD audit: Insights into the current state of management for neovascular age-related macular degeneration.Eye (London, England) · 2023Article
- Artificial Intelligence to Facilitate Clinical Trial Recruitment in Age-Related Macular Degeneration.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.